Revolution Medicines Inc. (RVMD) News
Filter RVMD News Items
RVMD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RVMD News Highlights
- For RVMD, its 30 day story count is now at 9.
- Over the past 12 days, RVMD's stories per day has been in a clear downtrend, falling by about 0.26 per 2 days.
- The most mentioned tickers in articles about RVMD are BEAT, ACRX and PR.
Latest RVMD News From Around the Web
Below are the latest news stories about REVOLUTION MEDICINES INC that investors may wish to consider to help them evaluate RVMD as an investment opportunity.
Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25%The latest analyst coverage could presage a bad day for Revolution Medicines, Inc. ( NASDAQ:RVMD ), with the analysts... |
Revolution Medicines First Quarter 2023 Earnings: Beats ExpectationsRevolution Medicines ( NASDAQ:RVMD ) First Quarter 2023 Results Key Financial Results Revenue: US$7.01m (down 7.4% from... |
Q1 2023 Revolution Medicines Inc Earnings CallQ1 2023 Revolution Medicines Inc Earnings Call |
Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue EstimatesRevolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 14.29% and 68.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate ProgressFirst Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) – progressing on plan Appointment of chief medical officer and key leaders across late-stage development and commercial planning $909.8 million in cash, cash equivalents and investments at the end of first quarter 2023 Conference call and webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clini |
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseAcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Wall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 27.2% in Revolution Medicines, Inc. (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2023 on Monday, May 8, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and pr |
Revolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy?Revolution Medicines, Inc. (RVMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns climbed after last week's 16% gain, institutional investors must be happyKey Insights Significantly high institutional ownership implies Revolution Medicines' stock price is sensitive to their... |